Controversial Treatments: An Updated Understanding of the Coronavirus Disease 2019

Overview

Journal J Med Virol

Specialty Microbiology

Date 2020 Mar 29

PMID 32219882

Citations 48

Authors

Cantong Zhang

Shaoying Huang

Fengping Zheng

Yong Dai

Affiliations

Soon will be listed here.

Abstract

An outbreak of severe acute respiratory syndrome-related coronavirus 2 infection has posed significant threats to international health and the economy. In the absence of specific treatment for this virus, there is an urgent need to learn from the experience and lessons in China. To reduce the case-fatality rate among coronavirus disease 2019 patients, we should not ignore the complications, such as RNAaemia, acute respiratory distress syndrome, and multiple organ dysfunction. To help understand the advantages and limitations of differential treatments, we provide a timely review and discuss the complications and corresponding major treatments, especially controversial ones such as antiviral therapy (remdesivir, ribavirin, and chloroquine), glucocorticoid therapy, extracorporeal support including an artificial liver system, and extracorporeal membrane oxygenation based on available evidence. As a result, we suggest that antiviral therapy and organ function support are vital to reduce mortality for mild patients and critical patients, respectively.

Citing Articles

The Assessment of the Spectrum of Preventive Measures Taken by Healthcare Providers During the COVID-19 Pandemic in India: A Survey-Based Study.

Srivastava N, Rathia S, Dey C, Shukla A, T P, Singh S Cureus. 2023; 15(6):e41073.

PMID: 37519624 PMC: 10375825. DOI: 10.7759/cureus.41073.

The epidemiology and therapeutic options for the COVID-19.

Li J, Shao J, Wang C, Li W Precis Clin Med. 2022; 3(2):71-84.

PMID: 35960683 PMC: 7376264. DOI: 10.1093/pcmedi/pbaa017.

Mapping Scientific Productivity Trends and Hotspots in Remdesivir Research Publications: A Bibliometric Study from 2016 to 2021.

Ogunsakin R, Ebenezer O, Jordaan M, Shapi M, Ginindza T Int J Environ Res Public Health. 2022; 19(14).

PMID: 35886696 PMC: 9318242. DOI: 10.3390/ijerph19148845.

Rapid review and meta-analysis of adverse events associated with molnupiravir in patients with COVID-19.

Amani B, Zareei S, Amani B Br J Clin Pharmacol. 2022; 88(10):4403-4411.

PMID: 35762036 PMC: 9349444. DOI: 10.1111/bcp.15449.

Developing an Effective Peptide-Based Vaccine for COVID-19: Preliminary Studies in Mice Models.

Yang H, Cao J, Lin X, Yue J, Zieneldien T, Kim J Viruses. 2022; 14(3).

PMID: 35336856 PMC: 8954996. DOI: 10.3390/v14030449.

References

Booth C, Matukas L, Tomlinson G, Rachlis A, Rose D, Dwosh H . Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003; 289(21):2801-9. DOI: 10.1001/jama.289.21.JOC30885. View

T S Lee D, Wing Y, Leung H, Sung J, Ng Y, Yiu G . Factors associated with psychosis among patients with severe acute respiratory syndrome: a case-control study. Clin Infect Dis. 2004; 39(8):1247-9. PMC: 7107870. DOI: 10.1086/424016. View

Gao H, Lu H, Cao B, Du B, Shang H, Gan J . Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med. 2013; 368(24):2277-85. DOI: 10.1056/NEJMoa1305584. View

Stutchfield B, Simpson K, Wigmore S . Systematic review and meta-analysis of survival following extracorporeal liver support. Br J Surg. 2011; 98(5):623-31. DOI: 10.1002/bjs.7418. View

Li G, De Clercq E . Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020; 19(3):149-150. DOI: 10.1038/d41573-020-00016-0. View

Agostini M, Andres E, Sims A, Graham R, Sheahan T, Lu X . Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio. 2018; 9(2). PMC: 5844999. DOI: 10.1128/mBio.00221-18. View

Mulangu S, Dodd L, Davey Jr R, Mbaya O, Proschan M, Mukadi D . A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. N Engl J Med. 2019; 381(24):2293-2303. PMC: 10680050. DOI: 10.1056/NEJMoa1910993. View

Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M . In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun. 2004; 323(1):264-8. PMC: 7092815. DOI: 10.1016/j.bbrc.2004.08.085. View

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y . Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395(10223):507-513. PMC: 7135076. DOI: 10.1016/S0140-6736(20)30211-7. View

10.

Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H . Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020; 8(5):475-481. PMC: 7102538. DOI: 10.1016/S2213-2600(20)30079-5. View

11.

Biot C, Daher W, Chavain N, Fandeur T, Khalife J, Dive D . Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. J Med Chem. 2006; 49(9):2845-9. DOI: 10.1021/jm0601856. View

12.

Davies A, Jones D, Bailey M, Beca J, Bellomo R, Blackwell N . Extracorporeal Membrane Oxygenation for 2009 Influenza A(H1N1) Acute Respiratory Distress Syndrome. JAMA. 2009; 302(17):1888-95. DOI: 10.1001/jama.2009.1535. View

13.

. [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi. 2020; 43(3):185-188. DOI: 10.3760/cma.j.issn.1001-0939.2020.03.009. View

14.

Lee N, Chan K, Hui D, Ng E, Wu A, Chiu R . Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol. 2004; 31(4):304-9. PMC: 7108318. DOI: 10.1016/j.jcv.2004.07.006. View

15.

Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C . Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4):420-422. PMC: 7164771. DOI: 10.1016/S2213-2600(20)30076-X. View

16.

Sung J, Wu A, Joynt G, Yuen K, Lee N, Chan P . Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. Thorax. 2004; 59(5):414-20. PMC: 1746995. DOI: 10.1136/thx.2003.014076. View

17.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J . Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061-1069. PMC: 7042881. DOI: 10.1001/jama.2020.1585. View

18.

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M . Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3):269-271. PMC: 7054408. DOI: 10.1038/s41422-020-0282-0. View

19.

Zhang C, Huang S, Zheng F, Dai Y . Controversial treatments: An updated understanding of the coronavirus disease 2019. J Med Virol. 2020; 92(9):1441-1448. PMC: 7228369. DOI: 10.1002/jmv.25788. View

20.

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J . Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18):1708-1720. PMC: 7092819. DOI: 10.1056/NEJMoa2002032. View